Monoclonal Antibody Infusion Therapy for COVID-19
The U.S. Food & Drug Administration (FDA) has authorized the emergency use of monoclonal antibody infusion therapy (mABs) as a treatment for COVID-19. If you have been diagnosed with COVID-19 and are at high risk for developing severe COVID-19, you may be eligible for monoclonal antibody treatment, which might prevent you from becoming sicker.
What Are Monoclonal Antibodies?
Antibodies are part of our natural defense against viruses such as SARS-CoV-2, the virus that causes COVID-19. But they take time for the body to make. Antibodies designed to attack COVID-19 have been developed, and in several studies have been shown to reduce the risk of progressing to severe COVID-19 and hospitalization when given early to people who test positive for COVID-19. This therapy is given as an infusion through an IV at Nash UNC's outpatient COVID Infusion Center.
What is Monoclonal Antibody (mAb) Prophylaxis?
mAb prophylaxis is post exposure prevention of COVID-19 disease. This treatment may help prevent COVID-19 infection for certain people who have been exposed to someone who is infected with COVID-19.
Who is eligible for mAb prophylaxis?
Speak with your primary care provider to find out if you are eligible for outpatient COVID treatment options.